<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111328</url>
  </required_header>
  <id_info>
    <org_study_id>2019-191-2</org_study_id>
    <nct_id>NCT04111328</nct_id>
  </id_info>
  <brief_title>the Effect of Different Drugs and Infusion Ways on Degree of Postoperative Comfort</brief_title>
  <official_title>the Effect of Different Drugs and Infusion Ways on Degree of Comfort for Patients Undergoing Spinal Neoplasm Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Hospital of China Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effect of different drugs and infusion ways on degree of postoperative
      comfort.Patients undergoing spinal neoplasm surgery receive different patient controlled
      analgesia(PCA) drugs postoperatively,one group is sufentanil,the other is hydromorphone. Then
      each drug group will be divided into two subgroups according to the infusion
      way,intravenously,subcutaneously. During the patient controlled analgesia period, patients'
      degree of comfort,pain score,sleep quality, the degree of side reaction will be recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale of Comfort level</measure>
    <time_frame>48 hours after the use of PCA.</time_frame>
    <description>The participants' comfort level of the PCA.&quot;0&quot; means extremely comfort, &quot;10&quot; means extremely discomfort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation score</measure>
    <time_frame>6hours,12hours,24hours and 48 hours after the use of PCA.</time_frame>
    <description>To evaluate the degree of sedation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of nausea</measure>
    <time_frame>6hours,12hours,24hours and 48 hours after the use of PCA.</time_frame>
    <description>&quot;0&quot; means no nausea and vomiting,&quot;1&quot; means only nausea,&quot;2&quot;means nausea and vomiting .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The degree of dizziness</measure>
    <time_frame>6hours,12hours,24hours and 48 hours after the use of PCA.</time_frame>
    <description>&quot;0&quot; means no dizziness,&quot;1&quot; means the time of dizziness less than 2 hours,&quot;2&quot; means the time of dizziness more than 2 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil diameter</measure>
    <time_frame>6hours,12hours,24hours and 48 hours after the use of PCA.</time_frame>
    <description>The average diameter of both pupils measuring by pupil pen.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pittsburgh sleep quality index</measure>
    <time_frame>1 day before the surgery,1 month after the surgery.</time_frame>
    <description>The quality of sleep.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Analgesia, Patient-Controlled</condition>
  <arm_group>
    <arm_group_label>sufentanil administration intravenously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentanil administration subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydromorphone administration intravenously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydromorphone administration subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentanil and dexmedetomidine intravenously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of sufentanil, dexmedetomidine,for patient-controlled analgesia is 3.0μg/Kg, dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentanil and dexmedetomidine subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of sufentanil ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydromorphone and dexmedetomidine intravenously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5ml/h, PCA dose 1ml, locking time 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydromorphone and dexmedetomidine subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of hydromorphone for patient-controlled analgesia is 0.2mg/Kg ,dexmedetomidine ,for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5ml/h, PCA dose 1 ml, locking time 15 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous sufentanil</intervention_name>
    <description>The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .</description>
    <arm_group_label>sufentanil administration intravenously</arm_group_label>
    <other_name>SI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous sufentanil</intervention_name>
    <description>The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.</description>
    <arm_group_label>sufentanil administration subcutaneously</arm_group_label>
    <other_name>SS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous hydromorphone</intervention_name>
    <description>The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .</description>
    <arm_group_label>hydromorphone administration intravenously</arm_group_label>
    <other_name>HI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous hydromorphone</intervention_name>
    <description>The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.</description>
    <arm_group_label>hydromorphone administration subcutaneously</arm_group_label>
    <other_name>HS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous sufentanil and dexmedetomidine</intervention_name>
    <description>The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .</description>
    <arm_group_label>sufentanil and dexmedetomidine intravenously</arm_group_label>
    <other_name>SDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous sufentanil and dexmedetomidine</intervention_name>
    <description>The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.</description>
    <arm_group_label>sufentanil and dexmedetomidine subcutaneously</arm_group_label>
    <other_name>SDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous hydromorphone and dexmedetomidine</intervention_name>
    <description>The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.</description>
    <arm_group_label>hydromorphone and dexmedetomidine intravenously</arm_group_label>
    <other_name>HDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous hydromorphone and dexmedetomidine</intervention_name>
    <description>The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously</description>
    <arm_group_label>hydromorphone and dexmedetomidine subcutaneously</arm_group_label>
    <other_name>HDS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) physical status I or II .

        Exclusion Criteria:

          -  history of severe heart, hepatic or renal disease,

          -  history of chronic pain condition or opioid use,

          -  body mass index (BMI) ≤18 or ≥30 kg/m2,

          -  alcohol or drug abuse,

          -  relevant drug allergy,

          -  inability to properly describe postoperative pain,

          -  inability to use PCA pump.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiao Wang</last_name>
    <phone>8618240223963</phone>
    <email>wangjiao9210@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hosipital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jiao wang</last_name>
      <phone>8618240223963</phone>
      <email>wangjiao9210@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Hospital of China Medical University</investigator_affiliation>
    <investigator_full_name>Jun Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

